Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Heart Institute Research Corporation
• Collaborator: Heart and Stroke Foundation of Ontario
• Treatments: Nicotine; Varenicline

Criteria

Inclusion Criteria:

• smoking at least 10 cigarettes/day in the month prior to admission

• patient has been diagnosed with acute coronary syndrome (includes patients admitted for unstable angina or acute myocardial infarction), elective percutaneous coronary intervention, or coronary artery bypass surgery at any point in time

• motivated to stop smoking

• geographically available for follow-up visits (i.e., live within 1 hour of the study centre)

Exclusion Criteria:

• have been using NRT, Zyban (or Wellbutrin), and/or Champix for more than 72 hours

• have serious cardiac arrhythmias (e.g., tachycardia), vasospastic disease (e.g., Buerger's disease, Prinzmetal's variant angina)

• have severe renal impairment or are on dialysis

• unable to read and understand English

• patient is pregnant or breastfeeding or planning on becoming pregnant during the study period